Drug Information

Drug (ID: DG00189) and It's Reported Resistant Information

Name	Cyclosporin A
Synonyms	Cyclosporin A; cyclosporine; Neoral; Cyclosporin; Ciclosporine; Sandimmun; Sang-35 Click to Show/Hide
Indication	In total 1 Indication(s) COVID-19 [ICD-11: 1D92] Phase 1 [1]
Structure
Drug Resistance Disease(s)	Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases) Breast cancer [ICD-11: 2C60] [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C62H111N11O12
IsoSMILES	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
InChI	1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
InChIKey	PMATZTZNYRCHOR-CGLBZJNRSA-N
PubChem CID	5284373
ChEBI ID	CHEBI:4031
TTD Drug ID	D0G7UX
VARIDT ID	DR00448
INTEDE ID	DR0321
DrugBank ID	DB00091

Type(s) of Resistant Mechanism of This Drug

EADR: Epigenetic Alteration of DNA, RNA or Protein

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Breast cancer [ICD-11: 2C60]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: hsa-miR-106b~25				[1]
Molecule Alteration	Expression		Up-regulation	Molecule Info
Resistant Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Inhibition	hsa04210
	miR106b~25 cluster/EP300/E-cadherin signaling pathway		Regulation	hsa05206
In Vitro Model	MTMECs cells	Breast	Homo sapiens (Human)	N.A.
Experiment for Molecule Alteration	RT-PCR
Experiment for Drug Resistance	Flow cytometry assay
Mechanism Description	miR-106b~25 cluster controls transporter-independent MDR by apoptosis evasion via downregulation of EP300.
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Histone acetyltransferase p300 (EP300)				[1]
Molecule Alteration	Expression		Down-regulation	Molecule Info
Resistant Disease	Breast cancer [ICD-11: 2C60.3]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Cell apoptosis		Inhibition	hsa04210
	miR106b~25 cluster/EP300/E-cadherin signaling pathway		Regulation	hsa05206
In Vitro Model	MTMECs cells	Breast	Homo sapiens (Human)	N.A.
Experiment for Molecule Alteration	Western blot analysis
Experiment for Drug Resistance	Flow cytometry assay
Mechanism Description	miR-106b~25 cluster controls transporter-independent MDR by apoptosis evasion via downregulation of EP300.

References

Ref 1	MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep. 2016 Feb;35(2):1170-8. doi: 10.3892/or.2015.4412. Epub 2015 Nov 12.